If you do business in Brazil then you know that everything
is published there in Portuguese, including ANVISA’s documents. It is necessary to translate everything
unless you can read Portuguese. I can’t,
so whenever something comes out I have to do a quick translation to get an idea
of how significant it is. Last week, ANVISA
published two new documents related to their future pharma serialization and
traceability mandate. They are important,
because they relate directly to the schedule and some of the requirements of
Brazil’s pharma serialization and traceability mandate.
…a comprehensive exploration of the intersection between healthcare supply chains, track and trace technology, standards and global regulatory compliance
DISCLAIMER: RxTrace contains some of the personal thoughts, ideas and opinions of RxTrace. The material contained in RxTrace is not legal advice. The writers of RxTrace are not lawyers. The reader must make their own decisions about the accuracy of the opinions expressed in RxTrace. Readers are encouraged to consult their own legal counsel and trading partners before taking any actions based on information found in RxTrace. RxTrace is not a vehicle for communicating the positions of any company, organization or individual other than RxTrace.